Thetis Pharmaceuticals
Manufacturing · Connecticut, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
12 Main St Ste 5, Essex, Connecticut, 06...Phone Number
(203) 936-8936Website
www.thetispharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Thetis Pharmaceuticals
Thetis is a biopharmaceutical company dedicated to improving the lives of patients suffering from autoimmune diseases and cancer. Thetis' proprietary HEALER technology platform enables the pharmaceutical development of Resolvins, a class of endogenous lipid mediators that promote the resolution of inflammation. Thetis' HEALER technology overcomes the stability, manufacturing, and formulation hurdles that have limited the development of Resolvins as pharmaceutical agents, unlocking their robust pharmacology to be developed as first-in-class drugs with composition of matter patent protection.Explore more
Thetis Pharmaceuticals Org Chart
JS
Chief Medical Officer
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Thetis Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Thetis Pharmaceuticals had a recent Job posting/layoffs
Check out if Thetis Pharmaceuticals is spiking on competitors!
Thetis Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Thetis Pharmaceuticals
Product Launch: Get notified when Thetis Pharmaceuticals launches new products
Check if Thetis Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Thetis Pharmaceuticals has new funding data
Earning: See what the market has to say on Thetis Pharmaceuticals recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Thetis Pharmaceuticals
Compare insights from companies similar to Thetis Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Thetis Pharmaceuticals
<$5M
1-10
Private
$24.5M
2011
FS
Frank SciavolinoCo-Founder & President & Chief Scientific Officer
Company Profile Activity
Activity Insights
Thetis Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Thetis Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Thetis Pharmaceuticals.
Thetis Pharmaceuticals financials insights
Gather financial insights about Thetis Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Series A
$5.7M
2016
Debt
$1.4M
Private Equity
$4.1M
2021
Debt
$89K
2022
Debt
$4.2M
2025
Debt
$9M
Thetis Pharmaceuticals Tech Stack
A closer look at the technologies used by Thetis Pharmaceuticals
See more technologies
Most Recent Scoops
Funding
Funding
Funding
Project
Spending/Investment
Funding
Project
Award, Spending/Investment
Event
will be attending the 2022 BIO International Convention conference as an exhibitor. The event will occur from June 13 to June 16, 2022.
Funding
Thetis Pharmaceuticals News & Media
Thetis Pharmaceuticals Presents New Preclinical and Clinical Data for TP-317 at ECCO 2025
ESSEX, Conn.--(BUSINESS WIRE)-- #IBD--Thetis Pharmaceuticals LLC (“Thetis”), a clinical-stage company developing TP-317, a first-in-class, small molecule drug candidate targeting the BLT1 receptor to treat inflammatory bowel disease (IBD), Crohn’s disease and ulcerative colitis, today announced the presentation of new preclinical and clinical data at the 20th Congress of the European Crohn’s and Colitis Organization (ECCO) in Berlin, Germany, February 19-22, 2025. “These new data further validatThetis Pharmaceuticals Secures an Additional $8.975 Million in Program-Related Investment Funds from the Helmsley Charitable Trust to Advance TP-317, an Oral BLT1 Agonist, into a Phase 1b Trial in Ulcerative Colitis Patients
ESSEX, Conn.--(BUSINESS WIRE)-- #BLT1--Thetis Pharmaceuticals LLC (“Thetis”), a clinical-stage company developing TP-317, a first-in-class, small molecule drug candidate targeting the BLT1 receptor to treat inflammatory bowel disease (IBD), Crohn’s disease and ulcerative colitis, today announced that the company has secured an additional $8.975 million in program-related investment funding in the form of a loan from The Leona M. and Harry B. Helmsley Charitable Trust (“Helmsley”), bringing HelmsThetis Pharmaceuticals Announces Appointment of Fabio Cataldi, M.D., to Board of Managers and Scientific Advisory Board
ESSEX, Conn.--(BUSINESS WIRE)-- #IBD--Thetis Pharmaceuticals Announces the Appointment of Fabio Cataldi, M.D., to the Company's Board of Managers and Scientific Advisory Board.Thetis Pharmaceuticals Announces Positive Initial Results From Phase 1a Study of TP-317 in Healthy Subjects
ESSEX, Conn.--(BUSINESS WIRE)-- #BLT1--Thetis Pharmaceuticals Announces Positive Initial Results From a Phase 1a Study of TP-317, a BLT1 Agonist, in Healthy Subjects.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Thetis Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Thetis is a biopharmaceutical company dedicated to improving the lives of patients suffering from autoimmune diseases and cancer. Thetis' proprietary HEALER technology platform enables the pharmaceutical development of Resolvins, a class of endogenous lipid mediators that promote the resolution of inflammation. Thetis' HEALER technology overcomes t... Read More
